🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Amgen Inc (4332)

Hong Kong
Currency in HKD
1,761.00
0.00(0.00%)
Closed
4332 Scorecard
Full Analysis
Has raised its dividend for 14 consecutive years
Trading near 52-week High
Fair Value
Day's Range
1,761.001,761.00
52 wk Range
1,761.001,761.00
Key Statistics
Edit
Bid/Ask
-
Prev. Close
1,850
Open
1,761
Day's Range
1,761-1,761
52 wk Range
1,761-1,761
Volume
-
Average Vol. (3m)
100
1-Year Change
0%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4332 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
328.13
Upside
+19.00%
Members' Sentiments
Bearish
Bullish
ProTips
18 analysts have revised their earnings downwards for the upcoming period
Show more

Amgen Inc Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Employees
25200

Compare 4332 to Peers and Sector

Metrics to compare
4332
Peers
Sector
Relationship
P/E Ratio
0.0x−1.7x−0.7x
PEG Ratio
0.00−0.010.00
Price / Book
0.0x2.0x2.6x
Price / LTM Sales
0.0x3.5x3.2x
Upside (Analyst Target)
0.0%44.5%47.1%
Fair Value Upside
Unlock19.3%7.3%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 7.88
Dividend Yield
0.49%
Industry Median 2.72%
Annualized Payout
9.0002
Paid quarterly
5-Years Growth
-
Growth Streak

People Also Watch

97.13
FTNT
+0.09%
641.87
KLAC
-1.61%
799.58
LLY
-0.50%
75.13
LRCX
-3.00%
40.54
SMCI
-8.20%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.